Paclitaxel and carboplatin with thoracic radiation locally advanced non-small-cell lung cancer

Research output: Contribution to journalArticle

Abstract

Combined-modality approaches integrating carboplatin (Paraplatin) and low doses of weekly paclitaxel (Taxol) with thoracic radiation therapy for prolonging survival in patients with locally advanced non-small-cell lung cancer have begun to replace the traditional approach of thoracic radiation alone. The addition of chemotherapy to thoracic radiation therapy has shown an impact on survival of these patients, especially those with good performance status and < 5% weight loss. Although dosage and schedule of administration continues to be a subject of controversy, both sequential and concurrent regimens are feasible and the toxicity profiles are acceptable.

Original languageEnglish (US)
Pages (from-to)54-59
Number of pages6
JournalOncology
Volume13
Issue number9 SUPPL. 4
StatePublished - 1999

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Thorax
Radiation
Radiotherapy
Survival
Weight Loss
Appointments and Schedules
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{45f3fac0fb884701ad8bd295e3418040,
title = "Paclitaxel and carboplatin with thoracic radiation locally advanced non-small-cell lung cancer",
abstract = "Combined-modality approaches integrating carboplatin (Paraplatin) and low doses of weekly paclitaxel (Taxol) with thoracic radiation therapy for prolonging survival in patients with locally advanced non-small-cell lung cancer have begun to replace the traditional approach of thoracic radiation alone. The addition of chemotherapy to thoracic radiation therapy has shown an impact on survival of these patients, especially those with good performance status and < 5{\%} weight loss. Although dosage and schedule of administration continues to be a subject of controversy, both sequential and concurrent regimens are feasible and the toxicity profiles are acceptable.",
author = "Chandra Belani",
year = "1999",
language = "English (US)",
volume = "13",
pages = "54--59",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "9 SUPPL. 4",

}

Paclitaxel and carboplatin with thoracic radiation locally advanced non-small-cell lung cancer. / Belani, Chandra.

In: Oncology, Vol. 13, No. 9 SUPPL. 4, 1999, p. 54-59.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Paclitaxel and carboplatin with thoracic radiation locally advanced non-small-cell lung cancer

AU - Belani, Chandra

PY - 1999

Y1 - 1999

N2 - Combined-modality approaches integrating carboplatin (Paraplatin) and low doses of weekly paclitaxel (Taxol) with thoracic radiation therapy for prolonging survival in patients with locally advanced non-small-cell lung cancer have begun to replace the traditional approach of thoracic radiation alone. The addition of chemotherapy to thoracic radiation therapy has shown an impact on survival of these patients, especially those with good performance status and < 5% weight loss. Although dosage and schedule of administration continues to be a subject of controversy, both sequential and concurrent regimens are feasible and the toxicity profiles are acceptable.

AB - Combined-modality approaches integrating carboplatin (Paraplatin) and low doses of weekly paclitaxel (Taxol) with thoracic radiation therapy for prolonging survival in patients with locally advanced non-small-cell lung cancer have begun to replace the traditional approach of thoracic radiation alone. The addition of chemotherapy to thoracic radiation therapy has shown an impact on survival of these patients, especially those with good performance status and < 5% weight loss. Although dosage and schedule of administration continues to be a subject of controversy, both sequential and concurrent regimens are feasible and the toxicity profiles are acceptable.

UR - http://www.scopus.com/inward/record.url?scp=24044504108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044504108&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 54

EP - 59

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 9 SUPPL. 4

ER -